Buffered Penicillin G Potassium
NDC Package 51662-1436-1

11-digit billing NDC: 51662143601
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Buffered Penicillin G Potassium is therapyBuffered Penicillin G Potassium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Marketed by Hf Acquisition Co Llc, Dba Healthfirst, this product is identified by NDC 51662-1436 and is authorized under FDA application ANDA065079.

Identification & Billing

NDC Package Code
51662-1436-1
Package Description
1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL
Product Code
51662-1436
11-Digit Billing Format
51662143601

Clinical Specifications

Proprietary Name
Buffered Penicillin G Potassium
Dosage Form
-
Usage Information
TherapyBuffered Penicillin G Potassium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Buffered Penicillin G Potassium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued.To reduce the development of drug-resistant bacteria and maintain the effectiveness of Penicillin G Potassium and other antibacterial drugs, Penicillin G Potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Regulatory & Marketing

Labeler Name
Hf Acquisition Co Llc, Dba Healthfirst
FDA Application #
ANDA065079
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
01-29-2020
End Marketing Date
08-18-2026
Listing Expiration
08-18-2026
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

J2540
Source: ASP
Penicillin g potassium inj
HCPCS Dosage 600000 UNITS
Units / Pkg 9

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 51662-1436-1 identifies a specific commercial package of 1 injection, powder, for solution in 1 vial of Buffered Penicillin G Potassium, labeled by Hf Acquisition Co Llc, Dba Healthfirst. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Hf Acquisition Co Llc, Dba Healthfirst on January 29, 2020. The current certification is valid through August 18, 2026.

How is this Hf Acquisition Co Llc, Dba Healthfirst product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 51662143601. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
51662-1436-1
11-Digit CMS (5-4-2)
51662-1436-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.